AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$HTFL

Farquhar John C.M. sold $1.4M of HTFL

Farquhar John C.M. (Chief Executive Officer) sold 27,230 shares of Heartflow, Inc. (HTFL) at $50.00 ($1.36M total) on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Farquhar John C.M.
Published Aug 25, 2026, 9:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HTFL
Bearish
medium confidence
Mentioned
$HTFL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HTFLBearishLow
01

Why it matters

The sale may affect short-term sentiment but likely has limited long-term effect.

02

Market read

Insider sale of $1.36M by CEO could prompt modest price movement.

03

What to watch

The sale was pre-arranged via 10b5-1, reducing informational content.

Relevance 5/10Novelty 5/10Timing: filing date 2026-08-25

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$HTFLBearishMedium confidence
Context

CEO John C.M. Farquhar sold 27,230 shares for $1.36M via a 10b5-1 plan.

Expected impact

Possible short-term dip as market digests the sale.

Evidence & confidence

CEO insider sales are closely watched; $1.36M is material for a mid-cap biotech.

Market effects

Sector

May raise concerns for other biotech insiders.

Regional

Limited to US biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

Insider sale could be routine under a pre-arranged plan, not a negative signal.

Key entities

  • Company
    Heartflow, Inc.

    Medical device company developing non-invasive coronary artery disease diagnostics.

  • Executive
    John C.M. Farquhar

    Chief Executive Officer of Heartflow.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HTFL insider trading history →

Related articles

SEP 13
$HTFLHigh

HTFL Soars After Q2 Beat And Raised 2026 Revenue Outlook

HeartFlow (HTFL) stock rose 9.63% after Q2 earnings beat and raised 2026 revenue outlook. Q2 revenue was $64.08M with 80.1% gross margin, but -55.8% profit margin. Company has strong liquidity with $162.55M cash and low debt. Analysts see near-term support at $46-$47 and resistance at $54-$56, with a 12-month target of $60 if growth continues.

timothysykes.com2 min
AUG 19
$HTFLMedAI 8/10

Why Heartflow Stock Soared Today

HeartFlow (HTFL) shares rose after the company raised its full-year revenue targets. Revenue grew 48% YoY to $64.1M in Q2, with adjusted gross margin increasing to 83.3%. The company now expects 40-42% revenue growth for 2026, up from prior forecasts. CEO John Farquhar cited improved operating leverage and scalability.

aol.com2 min